Provided by Tiger Fintech (Singapore) Pte. Ltd.

Natera

160.43
-2.9300-1.79%
Post-market: 160.430.00000.00%18:52 EDT
Volume:710.03K
Turnover:114.59M
Market Cap:21.91B
PE:-108.38
High:163.40
Open:162.57
Low:160.24
Close:163.36
Loading ...

Natera Inc. Announces Promising Results for Latitude™ MRD Assay in Colorectal Cancer Study at ESMO GI Congress

Reuters
·
07 Jul

Solomon Moshkevich, President of Clinical Diagnostics, Reports Disposal of Common Shares of Natera Inc

Reuters
·
04 Jul

Director Marcus Gail Boxer Reports Disposal of Common Shares in Natera Inc

Reuters
·
04 Jul

Steven Leonard Chapman, CEO and President, Reports Disposal of Common Shares of Natera Inc

Reuters
·
04 Jul

Natera Inc. Announces New Data Highlighting Clinical and Economic Benefits of Signatera in Colorectal Cancer Surveillance at ESMO GI Congress 2025

Reuters
·
02 Jul

Shares of Natera (NTRA) Fall as Executive Chairman Sells Company Stock

TIPRANKS
·
26 Jun

Barclays Sticks to Their Buy Rating for Natera (NTRA)

TIPRANKS
·
25 Jun

Matthew Rabinowitz, Executive Chairman, Reports Disposal of Common Shares of Natera Inc

Reuters
·
21 Jun

Natera Inc. Conducted Annual Stockholders Meeting

Reuters
·
19 Jun

Natera Inc. Releases 2024 Sustainability Report

Reuters
·
18 Jun

Analysts Offer Insights on Healthcare Companies: Natera (NTRA) and Wave Life Sciences (WVE)

TIPRANKS
·
10 Jun

Solomon Moshkevich, President of Clinical Diagnostics at Natera Inc., Reports Disposal of Common Shares

Reuters
·
05 Jun

CEO and President Steven Leonard Chapman Reports Disposal of Common Shares of Natera Inc

Reuters
·
05 Jun

Natera (NTRA) Receives a Buy from Leerink Partners

TIPRANKS
·
05 Jun

BRIEF-Natera Inc - Signatera Assay Now Covered By Medicare

Reuters
·
04 Jun

Natera Inc - Signatera Assay NOW Covered by Medicare

THOMSON REUTERS
·
04 Jun

Natera Inc. Secures Medicare Coverage for Signatera™ Genome-Based MRD Assay Across Multiple Cancer Types

Reuters
·
04 Jun

Natera Inc. Unveils Breakthrough Results in Pan-Cancer Study with Signatera Genome Assay at ASCO 2025, Showcasing 94% Sensitivity and 100% Specificity

Reuters
·
03 Jun

Stanley Druckenmiller's Duquesne dumps Alphabet, buys more Taiwan Semi and Coupang

Dow Jones
·
16 May

Natera Is Maintained at Overweight by Piper Sandler

Dow Jones
·
16 May